Clinical Trial Update: Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis Patients [Phase 1, Phase 2]

View source ↗

Summary

Early-phase (Phase 1/2) clinical trial evaluating SB012, given intrarectally, for active ulcerative colitis, assessing efficacy, pharmacokinetics, tolerability …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• SB012

Snippet

Sponsor: Sterna Biologicals GmbH & Co. KG | Conditions: Colitis, Ulcerative | Phase 1, Phase 2 | Status: COMPLETED